On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

PI3K Inhibitors Safe and Effective in CLL Patients

Updated data on the safety and effectiveness of three different phosphoinositide 3-kinase inhibitors (PI3K inhibitors) presented at the European Hematology Association (EHA) Congress show...
On location

Single-Agent Ibrutinib Leads to Durable Responses in CLL

In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), single-agent ibrutinib led to durable responses, according to...
On location

Pediatric Leukemia Patients May Benefit from CAR Therapy

Genetically reprogrammed T cells, which have been making waves in adult acute lymphocytic leukemia (ALL), have also shown promise in pediatric ALL patients, according...
On location

Updates on Novel Treatments for Leukemia

Three sessions at the American Association for Cancer Research Annual Meeting focused on promising, novel treatment options for patients with various forms of leukemia. In...
On location

Study Evaluates Safety of Cytotoxic T Lymphocytes for Rituximab-Refractory Epstein-Barr Virus

For patients who have undergone stem cell or organ transplantation, the drugs administered to prevent organ rejection can weaken the immune system, which can...

ASH Sickle Cell Disease Summit: A Call to Action

In mid-April, more than 60 experts in sickle cell disease (SCD), including clinicians and researchers, federal agency partners, representatives from industry, and other members...
On location

IOM/ACS Pediatric Oncology Workshop Highlights Survivorship Issues

On March 9-10, the Institute of Medicine’s (IOM’s) National Cancer Policy Forum (NCPF) and the American Cancer Society (ACS) sponsored a workshop on Comprehensive...
On location

Great Strides in Survivorship of Childhood Cancer Since the 1970s

More refined treatment and modern screening methods have led to improved long-term survival rates for children and young adults diagnosed with cancer – particularly...

Phase Ib Study Shows Vadastuximab Talirine and 7+3 Combination Is Safe in Patients with...

Results from a phase Ib study presented at the 2016 ASH Annual Meeting suggest that combining standard 7+3 chemotherapy with the investigational CD33-directed antibody...

The Inaugural ASH Meeting on Hematologic Malignancies: A Discussion With the Co-Chairs

New clinical and biologic data within lymphoid and myeloid malignancies, including newly completed clinical trials, novel drugs, and insight into the genetic basis of these varied diseases is coming so fast and...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.